AA
GANX icon

Armis Advisers’s Gain Therapeutics GANX Stock Holding History

Armis Advisers’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,750
Closed -$19.8K – 439
2025
Q3 		$19.8K Hold
10,750
– – ﹤0.01% 320
2025
Q2 		$18.6K Hold
10,750
– – ﹤0.01% 467
2025
Q1 		$22K Buy
+10,750
New +$23.8K ﹤0.01% 395

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armis Advisers's GANX Position: Q4 2025 in Review

Armis Advisers sold out of Gain Therapeutics (GANX) in Q4 2025, closing a stake of 10,750 shares — an estimated $19.8K sold.

Armis Advisers first reported a position in GANX in Q1 2025 and held it in 3 quarters. The position peaked at $22K in Q1 2025. 48 funds tracked by Wall St. Rank hold GANX as of Q4 2025.

  • Armis Advisers reported no remaining Gain Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Armis Advisers sold 10,750 Gain Therapeutics shares in Q4 2025, an estimated $19.8K.
  • Armis Advisers first reported a position in Gain Therapeutics in Q1 2025 and held it in 3 quarters.
  • Armis Advisers's Gain Therapeutics position peaked at $22K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2025.

Based on Armis Advisers's 13F filing for Q4 2025, filed 24 Mar 2026.